Un espoir de traitements pour les maladies infectieuses très négligées

[ Paris, Genève – 11 juin 2008 ]
L’Institut de Recherche pour le Développement (IRD) et la fondation Drugs for Neglected Diseases initiative (DNDi) annoncent aujourd’hui la mise en œuvre de projets de coopération scientifique pour le développement de médicaments contre la maladie de Chagas, la leishmaniose viscérale et  la maladie du Sommeil.
[English]

GlaxoSmithKline y Drugs for Neglected Diseases initiative (Iniciativa de Medicamentos para las Enfermedades Olvidadas) colaborarán en proyectos de investigación para cubrir necesidades de salud pública en los países en desarrollo

[ Madrid – 6 de marzo de 2008 ]
GlaxoSmithKline (GSK) y la organización sin ánimo de lucro Drugs for Neglected Diseases initiative (DNDi) han anunciado hoy un proyecto de colaboración en investigación sobre enfermedades tropicales olvidadas que afectan significativamente en países en desarrollo.
[English]

Resultados positivos para el tratamiento mejorado contra la enfermedad del sueño

[ Nueva Orleáns, Estados Unidos; París, Francia; Ginebra, Suiza – 9 de diciembre de 2008 ]
Los resultados de la Fase III del estudio clínico demuestran de manera concluyente que la Terapia Combinada a base de Nifurtimox y de Eflornitina (NECT por sus siglas en inglés) se tolera bien y resulta efectiva contra el estadío avanzado de la enfermedad del sueño causada por T. b. gambiense, una enfermedad potencialmente mortal que amenaza a 60 millones de personas en el África subsahariana.
[English] [Français]

Amélioration Thérapeutique contre la Maladie du Sommeil

[ La Nouvelle-Orléans, Etats-Unis; Paris, France; Genève, Suisse – 9 décembre 2008 ]
Les résultats d’une étude clinique de phase III démontrent que la Combinaison Thérapeutique de Nifurtimox et d’Eflornithine (NECT) est bien tolérée et efficace dans le traitement de la maladie du sommeil à T. b. gambiense au stade avancé, une maladie mortelle qui menace 60 millions de personnes en Afrique Sub-saharienne.
[English] [Español]

Sanofi-aventis and DNDi enter into a Collaboration Agreement on a New Drug for Sleeping Sickness, Fexinidazole

[ Paris, France, and Geneva, Switzerland – May 18, 2009 ]
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and the non-profit Drugs for Neglected Diseases initiative (DNDi) announced today that they have signed an agreement for the development, manufacturing and distribution of fexinidazole, a promising new drug for the treatment of human African trypanosomiasis, also known as sleeping sickness, a fatal disease that threatens 60 million people in Sub-Saharan Africa.
[Français]

NECT Added to WHO Essential Medicines List as Combination Treatment Against Sleeping Sickness

[ Geneva, Switzerland – May 15, 2009 ]
NECT (Nifurtimox-Eflornithine Combination Therapy) – a new treatment option against sleeping sickness, a fatal disease which threatens 60 million people across sub-Saharan Africa – has been added to the Essential Medicines List (EML) of the World Health Organization (WHO) based on the application submitted by the non-profit Drugs for Neglected Diseases initiative (DNDi) and supported by Epicentre and Médecins Sans Frontières (MSF).
[Français] [PDF]

SCYNEXIS and DNDi Extend Collaboration to Identify Drug Candidates to Treat Sleeping Sickness

[ December 11, 2008 ]
“SCYNEXIS believes that this collaborative project approach with DNDi can play an important role in improving the discovery and development of new therapies for neglected diseases,” said SCYNEXIS President & CEO Yves Ribeill. “We are pleased with the progress this alliance has achieved to date and look forward to continuing to apply our expertise in drug discovery and development to identify new drug candidates to treat sleeping sickness.”

Positive Results for Improved Treatment Against Sleeping Sickness

[ New Orleans, USA; Paris, France; Geneva, Switzerland – December 9, 2008]
Pivotal Phase III clinical trial results conclusively show that Nifurtimox-Eflornithine Combination Therapy (NECT) is well tolerated and effective against the advanced stage of T. b. gambiense sleeping sickness, a fatal disease that threatens 60 million people in sub-Saharan Africa.
[Français] [Español]